Lazard Asset Management’s Harmony Biosciences HRMY Stock Holding History
Bought
Maintained
Sold
Other funds holding HRMY
Lazard Asset Management's HRMY Position: Q3 2026 in Review
Lazard Asset Management increased its Harmony Biosciences (HRMY) stake by 4.5% in Q3 2026, buying an estimated $47.5K and bringing the position to 28,830 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1141.
Lazard Asset Management first reported a position in HRMY in Q2 2022 and has held it in 15 quarters since. The position peaked at $3.81M in Q1 2025. 358 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.
- Lazard Asset Management held 28,830 shares of Harmony Biosciences worth $1.13M as of Q3 2026.
- Lazard Asset Management bought 1,230 Harmony Biosciences shares in Q3 2026, an estimated $47.5K.
- Harmony Biosciences made up ﹤0.01% of Lazard Asset Management's portfolio in Q3 2026, its #1141 holding.
- Lazard Asset Management first reported a position in Harmony Biosciences in Q2 2022 and has held it in 15 quarters since.
- Lazard Asset Management's Harmony Biosciences position peaked at $3.81M in Q1 2025.
- 358 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.
Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.